Can antiphospholipid syndrome cause cardiomyopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Antiphospholipid Syndrome Cause Cardiomyopathy?

Yes, antiphospholipid syndrome (APS) can cause cardiomyopathy, most commonly presenting as dilated cardiomyopathy secondary to myocardial thrombotic microangiopathy, though this is a rare manifestation of the disease.

Mechanism and Pathophysiology

APS causes cardiomyopathy through thrombotic microangiopathy affecting the myocardium 1, 2. The antiphospholipid antibodies—particularly anti-β2-glycoprotein I antibodies—promote endothelial dysfunction, tissue factor expression, platelet activation, complement amplification, and neutrophil extracellular trap formation 2. This immunothrombotic process leads to microvascular ischemic injury within the myocardium, resulting in ventricular dysfunction.

Clinical Presentations

APS-related cardiomyopathy typically manifests as:

  • Dilated cardiomyopathy (most commonly reported) 3, 1, 4, 5
  • Hypertrophic non-obstructive cardiomyopathy (rare variant) 6
  • Biventricular dysfunction with potential progression to cardiogenic shock 7

The dilated form results from widespread myocardial thrombotic microangiopathy causing transmural necrosis and subsequent ventricular dilation 7.

Diagnostic Considerations

When evaluating suspected APS-related cardiomyopathy, look for:

  • Intracardiac thrombi on echocardiography (frequently present) 4
  • Markedly elevated anticardiolipin antibodies 4
  • Triple positivity (lupus anticoagulant + anticardiolipin + anti-β2GPI antibodies), which indicates highest risk 8, 9
  • Extracardiac thrombotic manifestations (brain, renal, iliac veins), though cardiomyopathy can be the sole manifestation 1

Prognosis and Management Implications

APS-associated cardiomyopathy confers a poor prognosis 7. The condition can be:

  • Resistant to standard heart failure therapy 4
  • Rapidly progressive to multiorgan failure 4
  • Potentially catastrophic when presenting as cardiogenic shock 7

However, early recognition and adequate anticoagulation with steroids can prevent clinical worsening 1, 5. Some patients respond well to this combination therapy 5.

Treatment Approach

For APS-related cardiomyopathy:

  1. Immediate anticoagulation with vitamin K antagonists (VKAs remain the cornerstone) 2, 10
  2. Corticosteroids for the inflammatory component 1, 5
  3. Plasmapheresis in catastrophic presentations 7
  4. Advanced therapies: mechanical circulatory support (ECMO) or heart transplantation may be necessary in refractory cases 7

Critical Pitfalls

  • Do not use DOACs in high-risk APS (triple positive or arterial thrombosis), as randomized trials show excess recurrent thrombosis, especially arterial events 2, 10
  • Recognize that cardiomyopathy may be the only manifestation of APS without other systemic thrombotic features 1
  • Maintain vigilance during perioperative periods when anticoagulation is altered, as thrombosis risk peaks during warfarin withdrawal or before adequate anticoagulation is achieved 3
  • Consider APS in young patients with unexplained dilated cardiomyopathy, particularly those with intracardiac thrombi 4

The 2023 ACR/EULAR classification criteria now incorporate cardiovascular manifestations including valvular and microvascular domains 2, 11, reflecting growing recognition of cardiac involvement in APS.

References

Research

[Research progress on risk factors and risk prediction of cardiovascular diseases related to antiphospholipid syndrome].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.